AMBRISENTAN for Pulmonary veno-occlusive disease: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 17 adverse event reports in the FDA FAERS database where AMBRISENTAN was used for Pulmonary veno-occlusive disease.
Most Reported Side Effects for AMBRISENTAN
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Dyspnoea | 13,367 | 15.5% | 652 | 6,217 |
| Death | 7,497 | 8.7% | 7,442 | 1,241 |
| Headache | 7,325 | 8.5% | 203 | 1,884 |
| Pneumonia | 4,693 | 5.4% | 368 | 3,802 |
| Dizziness | 4,561 | 5.3% | 93 | 1,261 |
| Fatigue | 4,436 | 5.2% | 145 | 1,312 |
| Diarrhoea | 4,312 | 5.0% | 168 | 1,512 |
| Nausea | 3,986 | 4.6% | 153 | 1,297 |
| Fluid retention | 3,927 | 4.6% | 212 | 2,212 |
| Malaise | 3,839 | 4.5% | 214 | 1,491 |
| Peripheral swelling | 3,461 | 4.0% | 128 | 1,107 |
| Cough | 3,067 | 3.6% | 85 | 899 |
| Nasal congestion | 3,019 | 3.5% | 36 | 423 |
| Oedema peripheral | 2,959 | 3.4% | 114 | 882 |
| Oedema | 2,651 | 3.1% | 109 | 923 |
Other Indications for AMBRISENTAN
Product used for unknown indication (35,884)
Pulmonary arterial hypertension (27,852)
Pulmonary hypertension (18,885)
Scleroderma (1,547)
Cor pulmonale chronic (879)
Connective tissue disorder (857)
Heart disease congenital (772)
Chronic obstructive pulmonary disease (460)
Portopulmonary hypertension (428)
Sleep apnoea syndrome (352)
Other Drugs Used for Pulmonary veno-occlusive disease
TREPROSTINIL (22)
EPOPROSTENOL (20)
SILDENAFIL (14)
IMATINIB (13)
MACITENTAN (11)
DEFIBROTIDE (8)
BOSENTAN (5)
SELEXIPAG (5)
TADALAFIL (5)